# Elite Pharmaceuticals, Inc. (ELTP) · Edgar & Edgarette company card

> Elite Pharmaceuticals (ELTP) grew revenue 77.1% in FY2026 to $149 million, operating margin 33.0% against a -3.8% median for pharmaceutical preparations, equity 71.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1053369 · fiscal year ended 2026-03-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ELTP) · [JSON](https://www.pops4.com/boards/company/ELTP.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $149M |
| Revenue growth, 1 year | 77.1% |
| Revenue growth per year | 46.6% |
| Operating margin | 33.0% (prior year 23.3%) |
| Net margin | 30.1% |
| Operating cash flow | $24M |
| Capital spending | $925,626 |
| Free cash flow | $23M |
| Cash | $30M |
| Long-term debt | — |
| Total assets | $138M |
| Total equity | $99M |
| Equity ÷ assets | 71.5% |
| Return on equity | 45.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 7.73 (safe zone)
- Piotroski F: 7 of 9 (solid)
- Health Harbor boat: Sound ship · one warning sign · revenue is hard to predict: its 80% range is ±27%
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $148.9M (FY2026). Experience: revenue up 77.1% on the year, up 46.6% a year over 4 years; operating margin 33.0%, up from 23.3%. Soundness: equity 71.5% of assets, return on equity 45.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $188.2M and $329.6M next year (method v4.1: its own 5-year record of growth weighed at 57% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $163.3M to $381.9M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 33.0% against a -3.8% median; growth 77.1% against 13.7%.

Range logged 2026-11-01, receipt 16a8a4a8dc45bb0b, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-11-03 ([filing](https://www.sec.gov/Archives/edgar/data/1053369/000149315226049707/0001493152-26-049707-index.htm))

## Recent filings

- 8-K · filed 2026-11-03 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1053369/000149315226049707/0001493152-26-049707-index.htm)
- 8-K · filed 2026-08-13 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1053369/000149315226037787/0001493152-26-037787-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1053369/000149315226037752/0001493152-26-037752-index.htm)
- 8-K · filed 2026-08-10 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1053369/000149315226036905/0001493152-26-036905-index.htm)
- 8-K · filed 2026-08-04 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1053369/000149315226035922/0001493152-26-035922-index.htm)
- 8-K · filed 2026-06-29 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1053369/000149315226031103/0001493152-26-031103-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001053369.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1053369

## Cite

POPS4, Edgar & Edgarette: Elite Pharmaceuticals, Inc. (ELTP) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/ELTP. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.